Sitagliptin Treatment in Patients With Type 2 DM After Kidney Transplant
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study is designed to look at the effect sitagliptin has on tacrolimus and sirolimus drug levels in kidney transplant patients. It is also designed to look at the side effects experienced in the transplant population.
| Condition | Intervention |
|---|---|
|
Kidney Transplant Type 2 Diabetes |
Drug: Administration of sitagliptin |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Sitagliptin Treatment in Patients With Type 2 Diabetes Mellitus After Kidney Transplant |
- Changes in pharmacokinetics [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
- To determine if there is a change in side effects with the addition of sitagliptin to the post-kidney transplant treatment regime. [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
- To determine the effect of sitagliptin on glucose lowering over 3 months as measured by the change in HgbA1c. [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
- To determine if the addition of sitagliptin changes tacrolimus or sirolimus drug levels in post-kidney transplant patients [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
- Determine tolerability of sitagliptin therapy in post-kidney transplant patients. [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 20 |
| Study Start Date: | April 2007 |
| Estimated Study Completion Date: | March 2010 |
| Estimated Primary Completion Date: | March 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 |
Drug: Administration of sitagliptin
Sitagliptin 100 mg daily for 3 months
Other Name: Januvia
|
Detailed Description:
Within the last six months, the FDA has approved sitagliptin phosphate as an oral drug that potentiates the effect of native GLP-1 through inhibition of DPP-4. It is approved for treatment of type 2 diabetes in adults as monotherapy or in combination with metformin or a TZD. It has several advantages over extenatide when considering its use in kidney transplant recipients:
- It is administered orally once a day
- Nausea occurred at a rate of only 1.4%
- Its potential of hypoglycemia is low
However, it may not be as potent, in terms of HbA1C with % change in HbA1C<1%. In addition there is not a lot of information on gastric emptying, although this is probably not as severe as exenatide, with fewer symptoms of nausea reported.
We propose to conduct a pilot study for using sitagliptin in patients who have both type 2 diabetes and who have received a kidney transplant. Our objectives are to study the effect of sitagliptin administration on side effect profiles, change in HbA1C, and the percentage of patients who require discontinuation of the drug as a result of major changes in immunosuppressant drug levels. The data will be used as preliminary data for a larger study that attempts to prevent or delay the onset of PTDM in kidney transplant recipients. We anticipate treating patients with both impaired fasting glucose and normoglycemia, given the high frequency of PTDM in the post-kidney transplant population.
Eligibility| Ages Eligible for Study: | 19 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Type 2 Diabetes Mellitus
- Most recent HbA1C 6.5-10%
- 1 year post kidney transplant
Exclusion Criteria:
- Patients treated primarily with insulin for their diabetes
- Kidney allograft not functional at entry or estimated creatinine clearance of <30 ml/min
- Clinical course complicated by persistent nausea
- severe gastroparesis
- Severe recurrent hypoglycemia (>1 hypoglycemic episode requiring the help of another person per week).
- Patients on dialysis therapy
- Unstable renal function in the preceding 3 months
- Serum transaminases >2 times normal at study entry
- Smokers
- Pregnant or planning to become pregnant
- Lactating
- Recipients of multi-organ transplants
- Unstable medical conditions which result in multiple hospitalizations or a severely restricted lifestyle
- Hemoglobin <10.0g/dl
- Use of digoxin
- Patients receiving their primary care outside of UNMC
- Inability to come to follow-up visits as a part of the protocol
- Patients not taking tacrolimus and sarolimus as part of their immunosuppressive therapy
Contacts and Locations| United States, Nebraska | |
| University of Nebraska Medical Center | |
| Omaha, Nebraska, United States, 68198-1230 | |
| Principal Investigator: | James T Lane, MD | University of Nebraska |
More Information
Additional Information:
No publications provided
| Responsible Party: | Dr. James Lane, University of Nebraska Medical Center |
| ClinicalTrials.gov Identifier: | NCT00466518 History of Changes |
| Other Study ID Numbers: | 475-06-FB |
| Study First Received: | April 26, 2007 |
| Last Updated: | January 11, 2010 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Nebraska:
|
Kidney transplant type 2 diabetes sitagliptin |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Sitagliptin Dipeptidyl-Peptidase IV Inhibitors |
Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Hypoglycemic Agents Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on May 23, 2013